A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer

A Multicenter, Open-Label Phase II Study To Evaluate The Efficacy And Safety Of ABSK021 In Combination With Chemotherapy With Or Without Toripalimab In Patients With Advanced Pancreatic Cancer

The goal of this clinical trial is to assess the efficacy and safety of Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab in patients with advanced pancreatic cancer. The main questions it aims to answer are:

• Whether the Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab is safe in patients with advanced pancreatic cancer.
• Whether the Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab is effective in patients with advanced pancreatic cancer.

Participants will be asked to complete the study procedures:

• Receive the administration of Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab about 24 weeks in study Part A or Part B.
• Receive the administration of Pimicotinib(ABSK021) about 24 weeks in study part 2.
• Complete the study procedures specified in the protocol, which is guided by researchers.

Study Overview

• Status: Recruiting
• Conditions: Advanced Pancreatic Cancer
• Intervention / Treatment: Drug: Pimicotinib (ABSK021)

Detailed Description

This is a phase II, open-label study to evaluate safety, tolerability, pharmacokinetics (PK), and clinical benefit of Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab in patients with advanced pancreatic cancer.

• Study Type: Interventional
• Enrollment (Estimated): 82
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: YUAN LU; Phone Number: +86-21-68910052; Email: clinical@abbisko.cn

Study Locations

• China
  • Chengdu, China
    • Recruiting
    • West China Hospital of Sichuan University
    • Contact: Dan Cao
    • Principal Investigator: Dan Cao
  • Ha'erbin, China
    • Recruiting
    • Harbin Medical University Cancer Hospital
    • Contact: Zhiwei Li
    • Principal Investigator: Zhiwei Li
  • Shanghai, China
    • Recruiting
    • Shanghai East Hospital Tongji University
    • Contact: Ming Quan
    • Principal Investigator: Ming Quan
  • Wuhan, China
    • Recruiting
    • Union Hospital Tongji Medical College Huazhong University of science and technolog
    • Principal Investigator: Tao Zhang
    • Contact: Tao Zhang
  • Shanghai
    • Shanghai, Shanghai, China
      • Recruiting
      • Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine
      • Contact: Liwei Wang
      • Principal Investigator: Liwei Wang

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Male and female aged 18-75 years old. The subjects must have informed consent to the study, and signed the written informed consent voluntarily.
• Diagnosis as non resectable local advanced or metastatic pancreatic cancer by histology or cytology.
• Measurable disease as defined by RECIST 1.1.
• Without systemic treatment for pancreatic cancer.
• ECOG physical strength score 0-2
• Estimated survival time >=3 months.
• The adequate bone marrow fuction and coagulation function

Exclusion Criteria:

• Known allergy or hypersensitivity to any components of the investigational drug product.
• Previous treatment with highly selective inhibitors targeting Colony Stimulating Factor 1 (CSF-1)/Colony Stimulating Factor 1 Receptor (CSF-1R).
• With Breast Cancer Gene 1/2 (BRCA1/2) gene mutation.
• With a history of other malignancies within 5 years.
• During the trial, other chemotherapy, targeted therapy, hormone therapy, immunotherapy, radiotherapy (except for local symptomatic radiotherapy) or traditional Chinese medicine must be used for anti-tumor treatment.
• With conditions that significantly affected the absorption of oral drug.
• Surgical treatment is required within 4 weeks before the first administration, or unhealed, infected, or dehiscence of previous surgical wounds.
• During the 2 weeks prior to the first administration of this study, the patient was receiving chronic systemic steroid treatment or any other form of immunosuppressive treatment.
• Concomitant use of strong inhibitors or inducers of Cytochrome P450 3A4 (CYP3A4) within 14 days prior to randomization.
• Previous peripheral neuropathy > grade 1 (Common Terminology Criteria for Adverse Events, version 5.0).
• Diagnosed with immune deficiency or interstitial lung disease.
• The patients were vaccinated within 4 weeks before the first treatment.
• Participated in any drug clinical trial within 4 weeks before the first treatment.
• Active central nervous system (CNS) metastases.
• Impaired cardiac function or clinically significant cardiac disease.
• Known active liver or biliary disease, or other diseases that may lead to abnormal liver function test results during the study.
• Known active infections from certain viruses, bacteria or parasites.
• Patients with refractory/uncontrolled ascites or pleural effusion.
• Pregnant or lactating women.
• Any other clinically significant comorbidities, which in the judgment of the Investigator, should not be included.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: ABSK021 with chemotherapy; There are 2 cohorts in both part A and Part B. In cohort 1, the participant will receive the treatment of ABSK021 in combination with chemotherapy (the Gemcitabine and nab-Pacilitaxel) , 3 weeks as one cycle, about 8 cycles in total.	Drug: Pimicotinib (ABSK021); The ABSK021 will be taken orally, once daily; The Gemcitabine and nab-Pacilitaxel will be administrated with intravenous infusion on day 1 and 8 of each cycle; The Toripalimab will be administrated with intravenous infusion on day 1 of each cycle.; Other Names: Gemcitabine; Toripalimab; nab-Pacilitaxel
Experimental: ABSK021 in combination with chemotherapy plus the Toripalimab; There are 2 cohorts in both part A and Part B. In cohort 2, the participant will receive the treatment of ABSK021 in combination with chemotherapy (the Gemcitabine and nab-Pacilitaxel), with Toripalimab, 3 weeks as one cycle, about 8 cycles in total.	Drug: Pimicotinib (ABSK021); The ABSK021 will be taken orally, once daily; The Gemcitabine and nab-Pacilitaxel will be administrated with intravenous infusion on day 1 and 8 of each cycle; The Toripalimab will be administrated with intravenous infusion on day 1 of each cycle.; Other Names: Gemcitabine; Toripalimab; nab-Pacilitaxel

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety Event Occurance	The Number of Participants With Adverse Event (AE), a Serious Adverse Event (SAE) and Dose Limiting Toxicities (DLT) Event.	From the day signed informed consent form to day 90 after the end of cycle 8 (each cycle is 21 days)
Objective Response Rate (ORR)	The Percentage of Participants with confirmed Complete Response and Partial Response, in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) (Version 1.1)	From the cycle 1 day 1 to the end of cycle 8 (each cycle is 21 days)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Duration of Response	Duration of response (DOR) is defined as the time from the date of the first documentation of confirmed response (Complete Response or Partial Response) to the first objective documentation of progressive disease (PD) per RECIST v1.1 per Investigator assessment, or to death due to any cause in the absence of documented PD.	From the cycle 1 day 1 to the end of cycle 8 (each cycle is 21 days)
Progression Free Survival	Progression-free survival (PFS) was defined as as the time from the first dose to the first objectively documented disease progression per RECIST v1.1 per Investigator assessment, or death due to any cause in the absence of documented progressive disease (PD). PFS was analyzed using Kaplan-Meier methods.	From the cycle 1 day 1 to the end of cycle 8 (each cycle is 21 days)
Overall Survival	Overall survival (OS) was defined as the time from first dose of study drug to death due to any cause. OS was calculated using the Kaplan-Meier method.	From the cycle 1 day 1 to the end of cycle 8 (each cycle is 21 days)
The exposure of ABSK021	The Area Under the Concentration Curve From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) Normalized by Dose.	From the cycle 1 day 1 to the end of cycle 8 (each cycle is 21 days)
The Maximum Concentration of ABSK021	Maximum Observed Concentration (Cmax)	From the cycle 1 day 1 to the end of cycle 8 (each cycle is 21 days)
The Minimum Concentration of ABSK021	Minimum Observed Concentration (Cmin)	From the cycle 1 day 1 to the end of cycle 8 (each cycle is 21 days)

Collaborators and Investigators

• Sponsor: Abbisko Therapeutics Co, Ltd

Study record dates

Study Major Dates

• Study Start (Actual): October 17, 2023
• Primary Completion (Estimated): December 30, 2025
• Study Completion (Estimated): December 29, 2026

Study Registration Dates

• First Submitted: October 20, 2023
• First Submitted That Met QC Criteria: October 26, 2023
• First Posted (Actual): November 1, 2023

Study Record Updates

• Last Update Posted (Actual): April 11, 2024
• Last Update Submitted That Met QC Criteria: April 10, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Endocrine System Diseases; Digestive System Neoplasms; Endocrine Gland Neoplasms; Pancreatic Diseases; Pancreatic Neoplasms; Molecular Mechanisms of Pharmacological Action; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Gemcitabine
• Other Study ID Numbers: ABSK021-202

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No